GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. Sarah Goldberg from Yale Cancer Center describes which patients with advanced NSCLC she seeks molecular marker testing on.


Dr. Ravi Salgia from the University of Chicago discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.


Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.


Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.


Dr. David Spigel, Sarah Cannon Cancer Center, gives his view on more widespread availability of new mutation tests.


Dr. Heather Wakelee, from Stanford University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.


Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, describes the main types of kidney cancer and discusses the differences in their management


Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.


Dr. Phil Bonomi, from Rush University, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

Direct download: GRACEcastUC-116_Lung-Video_Bonomi_Manage_Acquired_Resistance.m4v
Category:Lung-Cancer-Video -- posted at: 9:46pm PST

Dr. Karen Kelly, of the University of California, Davis, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.


Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.


Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.


Dr. David Spigel, Sarah Cannon Cancer Center, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.


Dr. Rosalyn Juergens, McMaster University, discusses the question of widespread availability of new mutation tests under the Canadian health care system.


Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.


Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

Direct download: GRACEcastUC-109_Lung-Video_Maintenance_Therapy_Advanced_NSCLC.m4v
Category:Lung-Cancer-Video -- posted at: 12:39am PST

Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).


Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).


Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, explains the range of options and his approach to second line treatment of kidney cancer.

Direct download: GRACEcastUC-111_Kidney-Video_Second_Line_Rx_Metastatic_Kidney_Cancer.m4v
Category:general -- posted at: 11:56pm PST

Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, gives his view on whether a supercomputer such as Watson will be able to use complex algorithms to improve cancer care.

Direct download: GRACEcastUC-110_CA-101-Video_Supercomputer_Improve_Cancer_Care.m4v
Category:Cancer-101-Video -- posted at: 11:55pm PST

Dr. Ravi Salgia, University of Chicago, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.


Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).


Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).


Dr. Karen Kelly, of the University of California, Davis expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.


Dr. David Spigel, Sarah Cannon Cancer Center, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

Direct download: GRACEcastUC-106_Lung-Video_Spigel_Manage_Acquired_Resistance.m4v
Category:Lung-Cancer-Video -- posted at: 12:43pm PST

Dr. Rosalyn Juergens, McMaster University, reviews her thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.


Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?

Direct download: GRACEcastUC-104_Lung-Video_EGFR_Mutation_After_Starting_Chemo.m4v
Category:Lung-Cancer-Video -- posted at: 12:18am PST

Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.


Dr. Phil Bonomi, from Rush University, discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.


Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, explains the rationale and introduces the current standards and some potential variants for systemic therapy in patients with apparently localized pancreatic cancer.


Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, explains the rationale and introduces the current standards and some potential variants for systemic therapy in patients with apparently localized pancreatic cancer.


Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, describes the role of surgery in the treatment of metastatic kidney cancer.


Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on, and the particular markers they prioritize.


Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, gives his view on more widespread availability of new mutation tests.


Dr. Ravi Salgia, University of Chicago, describes the CollabRx system, which matches patients with particular mutations to appropriate clinical trials.


Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.


Dr. Karen Kelly, of the University of California, Davis, provides her thoughts on whether to continue an effective treatment beyond 4-6 cycles in an effort to exhaust the possible benefit from that treatment.